Cover Image

Strengthening Pharmacoepidemiology in a Changing Research Environment: The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance ( ENCePP )

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Xavier Kurz, Catherine Cohet, Susana Perez‐Gutthann, Shar Rao, Helga Gardarsdottir
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Pharmacoepidemiology and Drug Safety
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Core Concepts in Pharmacoepidemiology: Time‐To‐Event Analysis Approaches in Pharmacoepidemiology
by: Gerd Rippin, et al.
Published: (2024)

Core Concepts in Pharmacoepidemiology: Principled Use of Artificial Intelligence and Machine Learning in Pharmacoepidemiology and Healthcare Research
by: Kathryn Rough, et al.
Published: (2024)

Advancing Research Transparency and Reproducibility in Pharmacoepidemiology
by: Shirley V. Wang, et al.
Published: (2025)

Core Concepts: Self‐Controlled Designs in Pharmacoepidemiology
by: Sophie H. Bots, et al.
Published: (2025)

Core Concepts in Pharmacoepidemiology: Quantitative Bias Analysis
by: Jeremy P. Brown, et al.
Published: (2024)

Patient and Public Involvement in Pharmacoepidemiological Research: An Environmental Scan of an Emerging Area
by: Rigoureau Julie, et al.
Published: (2025)

Advancing Health Equity in Europe: Explore, Tailor, Implement, and Evaluate (ETIE)—A Framework of Diversity and Fairness in Pharmacoepidemiologic Research
by: Enriqueta Vallejo‐Yagüe, et al.
Published: (2025)

Research Sprints: An Intensive 1‐Week Approach to Training Collaborative Work in Pharmacoepidemiologic Research
by: Mette Reilev, et al.
Published: (2025)

A Methodological Review of Simulation Studies Published in Pharmacoepidemiology and Drug Safety
by: Ryan Muddiman, et al.
Published: (2026)

10 Practical Considerations for the Conduct of Multi‐National/Database Studies in Pharmacoepidemiology
by: Kenneth K. C. Man, et al.
Published: (2025)

Keep Your Guard Up: The Potential Impact of Drug Shortages on Pharmacoepidemiological Studies
by: Araniy Santhireswaran, et al.
Published: (2024)

Use of Point‐in‐Time or Window Approach in the Case‐Crossover Design, Implications for Pharmacoepidemiologic Research Using Registries
by: Jesper Hallas, et al.
Published: (2024)

Impact of Pharmacovigilance Interventions Targeting Fluoroquinolones on Antibiotic Use in the Netherlands and the United Kingdom
by: Tomas Lasys, et al.
Published: (2025)

EpiCore —A Common Data Model for Pharmacoepidemiological Studies in Denmark, Norway, and Sweden
by: Peter Bjødstrup Jensen, et al.
Published: (2025)

Curriculum in Pharmacoepidemiology Training Programs: A Cross‐Sectional Study to Assess Educational Needs and Alignment With Core Competencies
by: Amie Goodin, et al.
Published: (2026)

Multiple Perspectives on the Need for Real‐World Evidence to Inform Regulatory and Health Technology Assessment Decision‐Making: Scoping Review and Stakeholder Interviews
by: Marieke S. Jansen, et al.
Published: (2025)

Impact of Additional Monitoring on Pharmacovigilance and Pharmacists' Role: A Scoping Review
by: Xabier Aizpurua‐Arruti, et al.
Published: (2025)

Adverse Event Assessment of Upadacitinib: A Pharmacovigilance Study Based on the FAERS Database
by: Jiayu Yuan, et al.
Published: (2024)

Antibiotics and Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome: Analysis of Brazilian Pharmacovigilance Registries
by: Marcelo Bueno de Camargo, et al.
Published: (2025)

Quality of Clinical Information in Pregnancy Pharmacovigilance Data Sources—A Contribution of the ConcePTION Project
by: Yrea R. J. van Rijt‐Weetink, et al.
Published: (2025)

A Real‐World Pharmacovigilance Study of FDA Adverse Event Reporting System Events for Obeticholic Acid
by: Le Hai, et al.
Published: (2025)

Recommendations to Enable Broader Use of Real‐World Evidence to Inform Decision‐Making Throughout Pharmacovigilance Signal Management
by: G. Niklas Norén, et al.
Published: (2025)

Masking in Active Comparator Designs in Pharmacovigilance: A Retrospective Bias Analysis on the Spontaneous Reporting of Thiazolidinediones and Cardiovascular Events
by: William Bai, et al.
Published: (2025)

Lessons learned from a multi‐data source research collaboration: The mirabegron post‐authorization safety study program
by: Stefan de Vogel, et al.
Published: (2024)

Validation of Clinical Practice Research Datalink (CPRD) Aurum Mother‐Baby Link
by: Catherine Vasilakis‐Scaramozza, et al.
Published: (2025)

Metadata for Data dIscoverability aNd Study rEplicability in obseRVAtional Studies (MINERVA): Development and Pilot of a Metadata List and Catalogue in Europe
by: Romin Pajouheshnia, et al.
Published: (2024)

Metadata for Data dIscoverability aNd Study rEplicability in obseRVAtional Studies (MINERVA): Lessons Learnt From the MINERVA Project in Europe
by: Rosa Gini, et al.
Published: (2024)

In Memoriam—Helle Kieler (1956–2024)
by: Carolyn E. Cesta, et al.
Published: (2025)

Studying the Impact of European Union Regulatory Interventions for Minimising Risks From Medicines: Lessons Learnt and Recommendations
by: Thomas Goedecke, et al.
Published: (2024)

A Descriptive Comparative Analysis of Safety Concerns Outlaid in the Risk Management Plans of the European Union and Japan
by: Teruyuki Honda, et al.
Published: (2025)

Impact of Regulatory Risk Communication on Thrombosis With Thrombocytopenia Syndrome for COVID‐19 Adenovirus Vector Vaccines on European Healthcare Professionals
by: Ella van Vliet, et al.
Published: (2024)

Effectiveness of the Additional Risk Minimisation Measures for Valproate Among Healthcare Professionals and Patients: A Cross‐Sectional Survey in Six European Countries
by: Sandrine Colas, et al.
Published: (2024)

The European Drug–Drug Interaction (EuroDDI) Study Protocol: A Cross‐Country Comparison of Drug–Drug Interaction Prevalence in the Older Community‐Dwelling Population
by: John E. Hughes, et al.
Published: (2025)

Evaluating Data Quality by Proxy: Can We Evaluate All Dimensions of the European Medicines Agency Data Quality Framework for Registry‐Based Post‐Authorization Safety Studies?
by: Pamela Dobay, et al.
Published: (2026)

A European, Observational, 3‐Year Cohort Comparative Study on the Safety of the Fixed Dose Combination Pravastatin 40 mg/Fenofibrate 160 mg vs. Statin Alone in Real Clinical Practice: The POSE Study
by: Nikolaos Papadopoulos, et al.
Published: (2024)

Effectiveness of Additional Risk Minimization Measures Related to Interstitial Lung Disease/Pneumonitis With Trastuzumab Deruxtecan Treatment of Breast Cancer in European Countries: Results and Learnings From a Post‐Authorization Safety Survey Among Physicians
by: Angelika Wientzek‐Fleischmann, et al.
Published: (2025)

The Medicines Intelligence Data Platform: A Population‐Based Data Resource From New South Wales, Australia
by: Helga Zoega, et al.
Published: (2024)

Changes in the Use of Hydrochlorothiazide and Other Antihypertensive Drugs in Switzerland in Association With the Swissmedic Safety Alert Regarding Non‐melanoma Skin Cancer: An Interrupted Time‐Series Analysis Using Swiss Claims Data
by: Tamino Zappalà, et al.
Published: (2024)

Assessing Research Impact With Bibliometrics and Altmetrics: The Case of the Canadian Network for Observational Drug Effect Studies ( CNODES )
by: Alexandra M. Yip, et al.
Published: (2026)

Comparing IPCW Models to Adjust for Informative Censoring During COVID ‐19 Using Data From the Clinical Practice Research Datalink
by: Gwen Aubrac, et al.
Published: (2025)